Vyome Holdings, Inc. last reported quarterly results on Aug 25, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $26,955 (-97.8% year over year) and diluted EPS of -$0.10. It usually reports 45–59 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 18, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 19, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 45–59 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 25, 2026
56 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
-97.8%
|
-1
-122.0%
|
-0.10
+100.0%
|
|
May 29, 2026
59 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
-97.2%
|
-1
-227.5%
|
-0.15
+100.0%
|
|
Nov 19, 2025
50 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
-98.5%
|
-8
-1439.7%
|
-3.12
+99.8%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
2
+6.4%
|
-1
+84.5%
|
-1,419.10
-2290.7%
|
|
Aug 14, 2024
45 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
Apr 4, 2024
4 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
|
Nov 9, 2023
40 days after quarter end
|
—
ended Sep 30, 2023
|
—
|
—
|
—
|
|
Aug 7, 2023
38 days after quarter end
|
—
ended Jun 30, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HIND (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Clemente, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1427570
- Former names
- ReShape Lifesciences Inc. (until Aug 14, 2025); OBALON THERAPEUTICS INC (until Jun 21, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.